What drug-pricing policy pressures could a blue wave bring?
- With Democrats controlling both chambers of Congress, scrutiny of most-favored-nation (MFN) agreements could intensify, and Democrats could also seek concessions from drugmakers in budget negotiations. However, the president has veto power, and Senate voting rules also constrain sweeping legislation. Bernstein expects more investigations and policy discussions in the near term, with actual action limited.
- Democratic policy documents address starting IRA drug-price negotiations earlier, incorporating international prices, adjusting protections for blockbuster orphan drugs, and lowering drug prices in the commercial market. Broader Medicare coverage could bring an offset in sales volume, but the ultimate impact will depend on net prices, payer mix, and how policies are implemented.
- Bernstein views the existing MFN agreements signed in November 2025 as a buffer for the remainder of the current administration’s term. The renewal of prescription drug user-fee authorization in September 2027 could become a bargaining point for seeking regulatory accountability and disclosure provisions. The firm expects policy signals to emerge gradually in 2027, and to become clearer only after the party primaries in early 2028.
What is supporting the pharmaceutical sector’s rerating?
- Over the past six months, pharmaceutical stocks have risen about 18%, and the forward P/E has climbed to 17.8x, about 1.5x below the 19.3x high reached in 20 years. Bernstein divides the rerating into two stages: from November 2025 to February 2026, easing policy pressure lifted the valuation to 16.1x, an increase of 1.7x; thereafter, generalist investors returned, adding a further 1.7x and bringing it to the current level.
- Returning capital is drawn by pharmaceutical stocks’ diversification value against non-AI assets and their defensive qualities relative to the AI supply chain; advances in innovation have also increased their appeal. Bernstein believes AI development is unlikely to disrupt pharmaceutical companies’ earnings models over the next five years, and that they could potentially become beneficiaries of AI over the longer term.
How do historical performance and valuation headroom constrain optimism?
- Bernstein’s election study shows that since 1990, pharmaceutical stocks have on average underperformed the S&P 500 following Democratic gains. However, post-election outcomes have varied widely, and the sector’s performance has generally been close to that of defensive industries such as utilities and consumer staples. Historical data therefore point to pressure on relative returns, but do not mean the outcome will necessarily repeat.
- The firm believes the election itself is unlikely to hurt near-term earnings, but policy headlines could unsettle generalist investors who have returned to the sector. If that makes them more cautious, Bernstein estimates that the P/E could contract by 1 to 1.5x. This valuation risk is tied to whether drug-pricing policy ultimately changes companies’ net pricing and whether investors continue to value the sector’s defensive qualities.